21,823 Shares in Kiniksa Pharmaceuticals International, plc $KNSA Acquired by Fred Alger Management LLC

Key Points

• Fred Alger Management LLC acquired a new position in Kiniksa Pharmaceuticals, purchasing 21,823 shares valued at approximately $485,000.
• Several analysts have upgraded Kiniksa's stock ratings, with Jefferies increasing the price target from $45.00 to $54.00 and six analysts rating the stock as "Buy".
• Insider trading activity shows notable sales, with the chief accounting officer selling 11,000 shares recently, which represents a 22.44% decrease in their ownership of the company.

Fred Alger Management LLC acquired a new stake in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 21,823 shares of the company's stock, valued at approximately $485,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Wealth Enhancement Advisory Services LLC bought a new stake in Kiniksa Pharmaceuticals International in the 1st quarter valued at $301,000. GAMMA Investing LLC boosted its position in shares of Kiniksa Pharmaceuticals International by 84.8% during the 1st quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock valued at $27,000 after acquiring an additional 568 shares in the last quarter. Deutsche Bank AG increased its stake in Kiniksa Pharmaceuticals International by 177.1% in the first quarter. Deutsche Bank AG now owns 394,522 shares of the company's stock valued at $8,762,000 after acquiring an additional 252,125 shares during the period. Victory Capital Management Inc. acquired a new position in Kiniksa Pharmaceuticals International in the first quarter worth about $1,184,000. Finally, Nuveen Asset Management LLC lifted its stake in Kiniksa Pharmaceuticals International by 7.3% during the fourth quarter. Nuveen Asset Management LLC now owns 795,612 shares of the company's stock worth $15,737,000 after purchasing an additional 54,361 shares during the period. 53.95% of the stock is owned by institutional investors.

Kiniksa Pharmaceuticals International Stock Up 0.2%

NASDAQ:KNSA traded up $0.09 during mid-day trading on Friday, reaching $37.10. 396,031 shares of the company were exchanged, compared to its average volume of 411,524. The stock has a market cap of $2.75 billion, a PE ratio of 927.73 and a beta of 0.20. Kiniksa Pharmaceuticals International, plc has a 12 month low of $17.82 and a 12 month high of $37.34. The company has a fifty day moving average of $31.86 and a 200 day moving average of $27.13.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last announced its quarterly earnings data on Tuesday, July 29th. The company reported $0.23 EPS for the quarter, beating analysts' consensus estimates of $0.18 by $0.05. The firm had revenue of $156.80 million for the quarter, compared to analyst estimates of $145.21 million. Kiniksa Pharmaceuticals International had a return on equity of 1.05% and a net margin of 0.90%. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. On average, equities research analysts anticipate that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current fiscal year.

Insider Transactions at Kiniksa Pharmaceuticals International

In other news, CAO Michael R. Megna sold 11,000 shares of the firm's stock in a transaction dated Wednesday, September 3rd. The shares were sold at an average price of $34.84, for a total value of $383,240.00. Following the transaction, the chief accounting officer owned 38,011 shares of the company's stock, valued at approximately $1,324,303.24. This trade represents a 22.44% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider John F. Paolini sold 29,325 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $32.55, for a total transaction of $954,528.75. Following the sale, the insider owned 57,403 shares of the company's stock, valued at approximately $1,868,467.65. This represents a 33.81% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 562,271 shares of company stock valued at $18,716,309. 53.48% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on KNSA shares. Wells Fargo & Company upped their price objective on Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the company an "overweight" rating in a research note on Wednesday, July 9th. Jefferies Financial Group upped their price target on Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a "buy" rating in a research report on Tuesday, July 29th. Wedbush restated an "outperform" rating and issued a $36.00 target price on shares of Kiniksa Pharmaceuticals International in a research note on Monday, July 21st. Finally, Wall Street Zen raised shares of Kiniksa Pharmaceuticals International from a "buy" rating to a "strong-buy" rating in a report on Sunday, September 7th. Six research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $41.17.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.